메뉴 건너뛰기




Volumn 29, Issue 5, 2009, Pages 1797-1801

Continuous finasteride therapy for benign prostate hypertrophy upgrades both neuroendorcine differentiation and aggressive prostate cancer

Author keywords

Acquired prostate cancer; BPH; Continuous and intermittent finasteride; Gleason score data; Serum CgA data

Indexed keywords

CHROMOGRANIN A; FINASTERIDE;

EID: 67650096861     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (11)

References (22)
  • 1
    • 48849083217 scopus 로고    scopus 로고
    • The REDUCE trial: Chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride
    • Musquera M, Fleshner NE, Finelle A and Zlotta AR: The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther 8: 1073-1079, 2008.
    • (2008) Expert Rev Anticancer Ther , vol.8 , pp. 1073-1079
    • Musquera, M.1    Fleshner, N.E.2    Finelle, A.3    Zlotta, A.R.4
  • 2
    • 0035060658 scopus 로고    scopus 로고
    • Treatment of localized prostate cancer with intermittent triple androgen blockade: Preliminary results in 110 consecutive patients
    • DOI 10.1634/theoncologist.6-2-177
    • Leibowitz RL and Tucker SJ: Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 6: 177-182, 2001. (Pubitemid 32328005)
    • (2001) Oncologist , vol.6 , Issue.2 , pp. 177-182
    • Leibowitz, R.L.1    Tucker, S.J.2
  • 3
    • 0033045720 scopus 로고    scopus 로고
    • Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland
    • DOI 10.1002/(SICI)1097-0045(19990701)40:2<105::AID-PROS6>3.0.CO;2-9
    • Kirby R, Robertson C, Turkes A, Griffiths K, Denis LJ, Boyle P, Altwein J and Schroeder F: Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group: Prostat 40: 105-114, 1999. (Pubitemid 29304701)
    • (1999) Prostate , vol.40 , Issue.2 , pp. 105-114
    • Kirby, R.1    Robertson, C.2    Turkes, A.3    Griffiths, K.4    Denis, L.J.5    Boyle, P.6    Altwein, J.7    Schroder, F.8
  • 5
    • 0036332341 scopus 로고    scopus 로고
    • Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients
    • Tarle M, Ahel MZ and Kovacic K: Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Anticancer Res 22: 2525-2529, 2002. (Pubitemid 34857095)
    • (2002) Anticancer Research , vol.22 , Issue.4 , pp. 2525-2529
    • Tarle, M.1    Ahel, M.Z.2    Kovacic, K.3
  • 6
    • 0035162585 scopus 로고    scopus 로고
    • Neuroendocrine pathogenesis in adenocarcinoma of the prostate
    • Hansson J and Abrahamsson PA: Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 12(Suppl 2): S145-152, 2001.
    • (2001) Ann Oncol , vol.12 , Issue.SUPPL. 2
    • Hansson, J.1    Abrahamsson, P.A.2
  • 7
    • 0028567767 scopus 로고
    • Immunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor
    • Frkovic-Grazio S, Kraljic I, Trnski D and Tarle M: Immunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor. Anticancer Res 14: 2151-2156, 1994.
    • (1994) Anticancer Res , vol.14 , pp. 2151-2156
    • Frkovic-Grazio, S.1    Kraljic, I.2    Trnski, D.3    Tarle, M.4
  • 9
    • 1842788109 scopus 로고    scopus 로고
    • Neuroendocrine Differentiation in Hormone Refractory Prostate Cancer Following Androgen Deprivation Therapy
    • DOI 10.1016/j.eururo.2003.11.032, PII S0302283804000193
    • Hirano D, Okada Y, Minei S, Takimoto Y and Nemoto N: Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45: 586-592, 2004. (Pubitemid 38481685)
    • (2004) European Urology , vol.45 , Issue.5 , pp. 586-592
    • Hirano, D.1    Okada, Y.2    Minei, S.3    Takimoto, Y.4    Nemoto, N.5
  • 10
    • 0033943048 scopus 로고    scopus 로고
    • Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell lines
    • Salido M, Vilches J and Lopez A: Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell lines. Histol Histopathol 15: 729-738, 2000. (Pubitemid 30488556)
    • (2000) Histology and Histopathology , vol.15 , Issue.3 , pp. 729-738
    • Salido, M.1    Vilches, J.2    Lopez, A.3
  • 12
    • 32044457933 scopus 로고    scopus 로고
    • Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?
    • Grover S, Lowensteyn I, Hajek D, Trachtenberg J, Coupal L and Marchand S: Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial? J Urol 175: 934-938, 2006.
    • (2006) J Urol , vol.175 , pp. 934-938
    • Grover, S.1    Lowensteyn, I.2    Hajek, D.3    Trachtenberg, J.4    Coupal, L.5    Marchand, S.6
  • 14
    • 0029656028 scopus 로고    scopus 로고
    • The effect of finasteride on prostate specific antigen: Review of available data
    • Guess AH, Gormley GJ, Stoner E and Oesterling JE: The effect of finasteride on prostate specific antigen: Review of available data. J Urol 156: 3-9, 1996. (Pubitemid 126426420)
    • (1996) Journal of Urology , vol.155 , Issue.1 , pp. 3-9
    • Guess, H.A.1    Gormley, G.J.2    Stoner, E.3    Oesterling, J.E.4
  • 15
    • 13444280440 scopus 로고    scopus 로고
    • Effects of finasteride on prostate volume and prostate-specific antigen
    • Chiu KY and Yong CR: Effects of finasteride on prostate volume and prostate-specific antigen. J Chin Med Assoc 67: 571-574, 2004. (Pubitemid 40202069)
    • (2004) Journal of the Chinese Medical Association , vol.67 , Issue.11 , pp. 571-574
    • Chiu, K.-Y.1    Yong, C.-R.2
  • 16
    • 34547751529 scopus 로고    scopus 로고
    • Serum tPSA, cPSA, related density parameters and chromogranin a as predictors of positive margins after radical prostatectomy
    • Custovic Z, Kraus O, Tomaskovic I and Tarle M: Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy. Anticancer Res 27: 2817-2822, 2007. (Pubitemid 47228003)
    • (2007) Anticancer Research , vol.27 , Issue.4 C , pp. 2817-2821
    • Custovic, Z.1    Kraus, O.2    Tomaskovic, I.3    Tarle, M.4
  • 17
    • 35348971983 scopus 로고    scopus 로고
    • Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer
    • Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A and Koutsilieris M: Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 27(5B): 3651-3660, 2007. (Pubitemid 47607515)
    • (2007) Anticancer Research , vol.27 , Issue.5 B , pp. 3651-3660
    • Revelos, K.1    Petraki, C.2    Scorilas, A.3    Stefanakis, S.4    Malovrouvas, D.5    Alevizopoulos, N.6    Kanellis, G.7    Halapas, A.8    Koutsilieris, M.9
  • 19
    • 33846289982 scopus 로고    scopus 로고
    • New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer
    • Ankerst DP and Thompson IM: New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer. Arch Ital Urol Androl 78: 154-156, 2006. (Pubitemid 46113694)
    • (2006) Archivio Italiano di Urologia e Andrologia , vol.78 , Issue.4 , pp. 154-156
    • Ankerst, D.P.1    Thompson, I.M.2
  • 20
    • 0036789162 scopus 로고    scopus 로고
    • Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma
    • Fixemer T, Remberger K and Bonkhoff H: Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 53: 118-123, 2002.
    • (2002) Prostate , vol.53 , pp. 118-123
    • Fixemer, T.1    Remberger, K.2    Bonkhoff, H.3
  • 22
    • 34547657069 scopus 로고    scopus 로고
    • Chemoprevention of prostate cancer: Agents and study designs
    • E pub
    • Thompson IM: Chemoprevention of prostate cancer: agents and study designs. J Urol 178: S9-S13, (E pub), 2007.
    • (2007) J Urol , vol.178
    • Thompson, I.M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.